iBio Inc is a publicly traded company operating in the Biotechnology industry. Its shares trade on NYSE MKT LLC under the ticker IBIO, with a market capitalization of approximately $83 million. A full business summary isn’t available for this company yet — the figures and signals on this page are sourced from live mark…
An institutional-grade, numbers-driven thesis on IBIO — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates iBio Inc (IBIO) 45/100 with a 12-month base-case forecast of $2.27 — +35.1% versus the current price of $1.68. iBio Inc trades at $1.68 in the Biotechnology sector, with a market capitalisation of $83.5M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for IBIO is $2.27, implying +35.1% versus the current price. The model's 12-month scenario range runs from $1.94 (bear) to $2.68 (bull), with a base case of $2.27.
On the fundamentals, iBio shows trailing revenue of $400000, revenue growth of -20.0% YoY. This page also tracks IBIO's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
IBIO currently carries a TradersQuant composite score of 45/100, which we read as a cautious signal. The Wall-Street analyst consensus is "buy". Our 12-month price target of $2.27 implies +35.1% from $1.68. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for IBIO is $2.27, about +35.1% versus the latest price of $1.68. Consensus is based on 12 analysts.
TradersQuant's 12-month model forecast for IBIO is a base case of $2.27, ranging from $1.94 (bear) to $2.68 (bull), an expected return of +35.3%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for IBIO over the next 12 months is $2.27 in the base case (bear $1.94, bull $2.68), versus today's price of $1.68. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for IBIO — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates IBIO's fair value at $2.06, implying +22.4% of expected upside versus the current price.
iBio does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
